Meridian Bioscience Inc

Find Ratings Reports
VIVO : NASDAQ : Health Care
$15.45 | %
Today's Range: 15.2 - 15.525
Avg. Daily Volume: 331800.0
06/23/17 - 4:00 PM ET

Financial Analysis


MERIDIAN BIOSCIENCE INC's gross profit margin for the second quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. MERIDIAN BIOSCIENCE INC is extremely liquid. Currently, the Quick Ratio is 4.11 which clearly shows the ability to cover any short-term cash needs. VIVO managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

During the same period, stockholders' equity ("net worth") has remained unchanged from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)54.1351.26
EBITDA ($mil)16.217.62
EBIT ($mil)14.1916.36
Net Income ($mil)9.319.09


Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)54.7548.95
Total Assets ($mil)251.9258.36
Total Debt ($mil)56.8859.84
Equity ($mil)170.83169.85


Profitability Q2 FY17 Q2 FY16
Gross Profit Margin65.6767.96
EBITDA Margin29.9234.37
Operating Margin26.2131.91
Sales Turnover0.790.75
Return on Assets11.8413.76
Return on Equity17.4620.93
Debt Q2 FY17 Q2 FY16
Current Ratio6.476.03
Debt/Capital0.250.26
Interest Expense0.410.04
Interest Coverage34.77380.42


Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)42.242.08
Div / share0.130.2
EPS0.220.21
Book value / share4.054.04
Institutional Own % n/a n/a
Avg Daily Volume329395.0446906.0

Valuation


HOLD. The current P/E ratio indicates a significant discount compared to an average of 44.62 for the Health Care Equipment & Supplies industry and a discount compared to the S&P 500 average of 25.75. To use another comparison, its price-to-book ratio of 3.78 indicates a premium versus the S&P 500 average of 3.09 and a discount versus the industry average of 5.11. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, MERIDIAN BIOSCIENCE INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
VIVO 21.55 Peers 44.62   VIVO 14.70 Peers 28.17

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

VIVO is trading at a significant discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

VIVO is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
VIVO 21.55 Peers 25.37   VIVO NM Peers 1.00

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

VIVO is trading at a discount to its peers.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

VIVO's negative PEG ratio makes this valuation measure meaningless.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
VIVO 3.78 Peers 5.11   VIVO -15.48 Peers 114.13

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

VIVO is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, VIVO is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
VIVO 3.25 Peers 5.26   VIVO 2.53 Peers 14.54

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

VIVO is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

VIVO significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades